Zydus Lifesciences has recently unveiled ANVIMO, a groundbreaking medication designed to prevent Cytomegalovirus (CMV) infection in patients undergoing haematopoietic stem cell and kidney transplants. The drug, which contains Letermovir, represents a significant advancement in transplant care by offering a safer and more cost-effective treatment option.
At 10:25 am today, Zydus Lifesciences Limited’s shares were trading at ₹877.90, up by ₹6.25 or 0.72 per cent on the NSE. The company has managed to reduce the cost of CMV prophylaxis by a staggering 91 per cent, bringing down the monthly treatment price from over ₹5 lakh to a much more affordable level. ANVIMO is available in 240 mg and 480 mg dosages and has demonstrated bioequivalence with the reference drug.
CMV infection is a crucial complication in transplant patients, which can lead to graft failure and prolonged hospital stays. Previous treatments such as ganciclovir and valganciclovir had notable limitations, including toxicity and bone marrow suppression. Letermovir offers a well-tolerated alternative with improved safety profiles.
Dr. Sharvil Patel, the Managing Director of Zydus Lifesciences, emphasized the company’s dedication to providing accessible healthcare solutions. The launch of ANVIMO aims to enhance survival rates and improve the quality of life for transplant patients by making essential treatment more accessible.
Published on March 5, 2025.
